Artemisinin resistance and malaria vaccines

A health worker prepares a vaccine from a bottle. Copyright: UNICEF Ethiopia/2014/Bizuwerk, CC BY-NC-ND 2.0

Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.

Listen on Apple PodcastsListen on SpotifyListen on Google PodcastsListen on StitcherListen on OvercastListen on Amazon MusicListen on CastboxListen on Podcast AddictListen on Pocket CastsListen on iHeartRadioListen on PandoraRSS Feed

Episode 39

 With the confirmation that malaria parasites in Rwanda have developed resistance to artemisinin — a first-line drug used to treat malaria, which kills around 400,000 people a year worldwide — public health teams in Africa are asking what this could mean for the battle against malaria. Elsewhere on the continent, malaria vaccine trials have reported success.

This week on Africa Science Focus, reporter Charles Pensulo speaks to Karen Barnes from the University of Cape Town, who leads the Worldwide Antimalarial Resistance Network’s Southern Africa Regional Centre, and malaria specialist Elizabeth Juma, a medical officer with the World Health Organization.

And, in this week’s Q&A segment, Wakin Octavia from Henry Henderson Institute in Malawi has a question about chemistry.

Is there something you want to know about life, health or science in Africa? Send us your questions from anywhere in the world and we’ll find an expert to answer them — text or voice message via WhatsApp to +254799042513.

Africa Science Focus, with Selly Amutabi.

This programme was funded by the European Journalism Centre, through the European Development Journalism Grants programme, with support from the Bill & Melinda Gates Foundation.

Bill & Melinda Gates Foundation